Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
Date:11/9/2011

SAN DIEGO, Nov. 9, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the third quarter ended September 30, 2011.

"We are focused on submitting our response to the FDA for the lorcaserin complete response letter around year-end and filing the lorcaserin marketing authorization application with the European Medicines Agency in the first half of next year," stated Jack Lief, Arena's President and Chief Executive Officer. "With our lorcaserin program, we have the potential to provide a completely new treatment option to help patients reduce their weight and improve co-morbid conditions associated with obesity."

Research and development expenses continued to decline in the third quarter of 2011 to $15.0 million, compared to $20.2 million in the third quarter of 2010. Research and development expenses in the first nine months of 2011 declined to $45.6 million from $59.0 million in the first nine months of 2010. These decreases are primarily attributable to Arena's first quarter 2011 workforce reduction and ongoing cost-containment efforts, as well as completion of the Phase 3 lorcaserin clinical trials. General and administrative expenses decreased to $6.0 million in the third quarter of 2011, compared to $6.9 million in the third quarter of 2010, and $19.0 million in the first nine months of 2011, compared to $20.6 million in the first nine months of 2010.

Total interest and other expense in the third quarter of 2011 decreased to $3.4 million, compared to $14.5 million in the third quarter of 2010. Total interest and other expense in the first nine months of 2011 decreased to $21.1 million, compared to $22.4 million in the first nine months of 2010. These decreases are primarily attributable to a reduction in interest expense resulting from Arena's principal prepayments on its Deerfield loan of $20.0 million in Janu
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
2. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
3. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
4. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
5. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
6. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
7. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
8. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
9. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
10. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
11. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... /PRNewswire-iReach/ -- Dr. Michael Gabriel of a prominent ... a recent study, which shows how grief in pregnancy may ... According to US News , ... likely than others to grow up overweight or obese, even ... were two specific types of stress that caused obesity: "Children ...
(Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
(Date:7/24/2014)... Germany , and MARSEILLE, France ... , Exclusive global license from University of ... including next-generation sequencing (NGS) gene panels, for blood cancers  ... by new test, indicate favorable prognosis for patients with ... QIAGEN sees potential for developing companion diagnostics to guide ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5
... Oct. 28 IRIDEX Corporation (Nasdaq: IRIX ) today ... after the market closes on Thursday, November 4, 2010. ... a conference call with the investment community at 5:00 ... 2010 to discuss the results of the quarter and ...
... SAN DIEGO, Oct. 28 ASTRO Booth # 201 ... will highlight its new TrueBeam™ system for fast, powerful and ... American Society for Radiation Oncology (ASTRO) meeting in San Diego ... as new software capabilities designed to make cancer treatments faster, ...
Cached Medicine Technology:Varian Medical Systems to Exhibit TrueBeam™ System for Image-Guided Cancer Treatments and New Software Capabilities at ASTRO Meeting in San Diego 2Varian Medical Systems to Exhibit TrueBeam™ System for Image-Guided Cancer Treatments and New Software Capabilities at ASTRO Meeting in San Diego 3
(Date:7/27/2014)... 28, 2014 Zensah®, the leader in compression ... include a wrist support . The wrist support features ... area. , Lateral and Medial Epicondylitis, more commonly referred to ... which there is inflammation of the tendons attached to the ... wrist pain, the muscles that work the wrist and fingers ...
(Date:7/27/2014)... Petersburg, FL (PRWEB) July 28, 2014 ... water, and that is the key to the power ... our skin," says Kathy Heshelow, founder of Sublime Beauty®. ... topical Hyaluronic serum such as ours improves skin ... in the skin, key to a healthy and beautiful ...
(Date:7/27/2014)... 2014 Recently, Wdsshop.de, a reliable online supplier ... of fabulous prom dresses on its website. Now, ... up to 58% off. , “We are pleased to add ... They are specially created for those who are in need ... and vivid in style. I think our clients will love ...
(Date:7/27/2014)... Detroit, MI (PRWEB) July 27, 2014 ... the public with organic ways to achieve a younger ... eye cream buyer's guide to help men and women ... . , The details that are presented in the ... range of price information for consumers. On drawback to ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 Bags underneath the ... suffer from globally and there are a range of new ... is now promoting a baggy eyes serum review that is ... , The review explores the issues with baggy eyes and ... appearance for serum users. The guide also provides a detailed ...
Breaking Medicine News(10 mins):Health News:Zensah® Releases New Wrist Support 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2Health News:Wdsshop.de Unveils New Prom Dresses To Expand The Online Market 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:Baggy Eyes Serum Review Posted for Men and Women at Cherry News Website 2
... serious concern over growing problems due to use of ... Empowerment Meira Kumar today suggested effective monitoring // and ... ,There is a need to establish effective drug use ... the northeastern region,Kumar said while releasing a monograph on ...
... cholesterol-decreasing medications like millions of Americans. However she does ... she is taking part in a different clinical study ... view the benefits of Lipitor on the immune system ... sclerosis (ALS). ,Physicians at the Methodist NI's ...
... 24 years, bled to death following delivery of a stillborn baby, ... mother’s death, would now be offered a ?300,000 compensation for the ... duty in her case. ,She was admitted to the ... told that her baby had passed away in the uterus and ...
... business model for the state-of-the-art Institute of Liver and Biliary ... ,The model approved by the Cabinet at its meeting ... to be self-sufficient in nine years' time, an official spokesman ... medical equipment would be borne by Delhi Government., ,The ...
... ,The effects of zolpidem on three patients were studied for ... rehabilitation experts reveal that they are in a condition where ... interaction and responses, having signs of movement, sleep and breathing ... the patients every morning. ,An improvement was seen ...
... be a ray of hope for men, who are holed ... from available treatment measures//. An exercise by scientists involving rabbits, ... engineer an artificial penis, may be the answer for non-treatable ... adult male rabbits were introduced with a graft made from ...
Cached Medicine News:Health News:Study Aims At The Immune System In Patients With Lou Gehrig's Disease 2Health News:?300,000 Compensation For Family After Death Of Daughter Following Deliver 2
Irrigating Cystotome, Straight, 25 g. Overall length 15 mm. 5/box....
Irrigating Capsulorhexis Cystotome. Formed blunt tip, 25 g. Overall length 22 mm. 5/box....
Irrigating Cystotome, formed, 23 g., 12 mm curved tip. Overall length 14 mm. 5/box....
Retrobulbar Needle, 25 g. Atkinson style bevel. Overall length 38 mm. 5/box....
Medicine Products: